BRAF and low grade glioma: In consideration of this, MEK inhibitors such as selumetinib and trametinib have recently been used in the treatment of progressive and recurrent low-grade gliomas in children, demonstrating a 2-year PFS of up to 69% [34]; their efficacy is likely to be greatest in patients with BRAF V600 mutations.